The Dark Side Of Curcumin.pdf

This letter highlights the potential drawbacks of curcumin, a popular natural supplement derived from the plant Curcuma longa, despite its widespread use and claimed health benefits. The authors, from the University of Seville and Hospital Universitario de Valme, address the growing body of evidence suggesting that curcumin may not be as effective and safe as previously thought.

Key Points:

1. Low Bioavailability: Oral doses of curcumin result in very low plasma concentrations (nanomolar range), limiting its potential therapeutic effect, especially for systemic conditions like cancer.

2. Metabolism and Clearance: Extensive metabolism and rapid clearance from the gastrointestinal tract further reduce curcumin's bioavailability after oral ingestion.

3. Limited Clinical Efficacy:
- Studies show that curcumin concentrations required for anticancer activity in vitro are not achievable orally in humans.
- Clinical trials testing curcumin for various diseases, including cancer, have yielded mixed or negative results due to its poor bioavailability.

4. Safety Concerns:
- Curcumin has been linked to DNA damage and chromosomal alterations at concentrations similar to those associated with beneficial effects, raising concerns about its safety.
- A National Toxicology Program report (1993) found that long-term consumption of turmeric oleoresin (high in curcumin) led to gastrointestinal toxicity and possible carcinogenic effects in rats and mice.

5. Strategies for Overcoming Bioavailability:
- Combining curcumin with piperine (bioperine) has been proposed to enhance bioavailability, but this strategy should be used cautiously due to potential drug interactions.

The authors urge a balanced perspective on curcumin's use, acknowledging its potential benefits while recognizing the limitations and safety concerns associated with oral administration. They emphasize the need for further research to develop effective delivery methods for maximizing curcumin's therapeutic potential.